Abstract #3041

Camelid single-domain antibodies bioconjugate for the magnetic resonance imaging of Alzheimer’s disease.

Clémence Dudeffant ¹, Matthias Vandesquille², Tengfei Li³, Christelle Ganneau², Ihsen Youssef³, Benoît Delatour³, Pierre Lafaye⁴, Sylvie Bay², and Marc Dhenain¹

¹Molecular Imaging Research Center (MIRCen), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Fontenay aux Roses, France, ²Unité de Chimie des Biomolécules, Institut Pasteur, Paris, France, ³Institut du cerveau et de la moelle épinière (ICM), Paris, France, ⁴Plateforme d’Ingénierie des Anticorps, Institut Pasteur, Paris, France

Detection of intracerebral targets with imaging probes is challenging due to the non-permissive nature of blood-brain barrier (BBB). Camelid single-domain antibody-fragments (VHH) are small and stable antibodies able to potentially cross the BBB. Here, we selected VHH specifically targeting amyloid-beta deposits, one of the main lesions of Alzheimer’s disease and labeled them with the contrastophore gadolinium. These innovative contrast agents allowed MRI detection of amyloid deposits in postmortem brain tissues of a mouse model of amyloidosis. The ability to produce VHH conjugates that cross the BBB opens the way for future development of tailored imaging probes targeting intracerebral antigens.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.